Clinical trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-02-28

PhasePHASE3

Study timeline

Study start (actual)2024-02-28Date precision: day

Registry last updated2026-10-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Early Breast Cancerunresolved

Interventions

RibociclibDRUG · verified · RxNorm: ribociclib

LetrozoleDRUG · verified · RxNorm: letrozole

AnsastrozoleDRUG

GoserelinDRUG · verified · RxNorm: goserelin

LeuprolideDRUG · verified · RxNorm: leuprolide

ExemestaneDRUG · verified · RxNorm: exemestane

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

SeoulSouth Korea6 MontrealQuebec, Canada3 Porto AlegreRio Grande do Sul, Brazil3 PortoPortugal3 HoustonTexas, United States2 BostonMassachusetts, United States2 TorontoOntario, Canada2 BerlinGermany2 Washington D.C.District of Columbia, United States2 MinneapolisMinnesota, United States2 DenverColorado, United States2 TaipeiTaiwan2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05827081 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.